Lilly's Greed Steered Course Over Zyprexa: Official

Law360, New York (March 10, 2008, 12:00 AM EDT) -- As the first state trial over Zyprexa begins to unfold, a former officer with the U.S. Food and Drug Administration has asserted that Eli Lilly & Co. brushed off the risks associated with the popular schizophrenia drug in order to continue raking in profits from the medication's sale.

John Gueriguian testified Friday that the pharmaceutical giant had elected to put profits over people. Gueriguian was serving as a witness for the state of Alaska, one of nine states suing Lilly over the controversial drug, according to...
To view the full article, register now.